Klivira
Request demo

Optimizing Allergy & Immunology Denial Management with Automation

For allergy and immunology practices, effective allergy & immunology denial management is critical to financial health, especially given the prevalence of high-cost biologics, IVIG, and complex immunotherapies.

Managing denials in allergy & immunology presents unique challenges, from deciphering complex payer policies for novel treatments to ensuring timely appeals for high-value services. Manual processes often lead to missed deadlines, inconsistent documentation, and significant administrative burden, directly impacting the revenue cycle. Klivira's platform automates the intricate denial workflow, transforming a reactive process into a proactive strategy for your practice.

The Challenge of Allergy & Immunology Denials

Allergy & immunology practices frequently encounter denials for high-volume prior authorization categories such as asthma biologics (e.g., Xolair, Dupixent, Nucala), IVIG/SCIG, and allergen immunotherapy. These treatments often require extensive clinical documentation to demonstrate medical necessity, leading to a high potential for denials related to insufficient information or policy interpretation. Manually parsing X12 CARC/RARC codes and payer-specific denial reasons for these complex cases demands specialized staff expertise and significant time.

Limitations of Manual Denial Workflows in A&I

Without automation, the post-denial workflow for allergy & immunology services is prone to specific failure modes. Staff must manually track appeal deadlines, pull detailed clinical notes from EMRs (often across multiple visits) to support the efficacy of biologics or immunotherapy, and draft payer-specific appeal letters. This manual burden often results in timely-filing breaches, incomplete appeal packets, and eligible appeals being abandoned due to capacity constraints, directly impacting revenue for critical patient care.

Klivira's Automated Denial Management for Allergy & Immunology

Klivira integrates seamlessly into your existing EMR and revenue cycle systems to automate the entire denial management lifecycle for allergy & immunology claims. We ingest denial information from all channels, including X12 835 (remittance advice), X12 277 (claim status), Da Vinci PAS ClaimResponse, and payer portal status events. Our system then normalizes X12 CARC/RARC codes and payer-specific variations into a uniform reason set, ensuring accurate categorization for even the most complex allergy and immunology denials.

Intelligent Appeal Packet Assembly and Submission

For clinical-necessity denials common in allergy & immunology, Klivira automatically assembles comprehensive appeal packets. Leveraging SMART on FHIR, our platform retrieves relevant clinical documentation from your EMR, such as detailed progress notes, lab results (e.g., IgE levels, eosinophil counts), and prior-line therapy history, which are crucial for biologics and IVIG appeals. Appeals are then submitted via the payer’s preferred channel (API, fax, PAS-conformant resubmission) with automated tracking and timely-filing window enforcement to prevent lost revenue.

Proactive Insights and Continuous Improvement

Beyond individual appeal resolution, Klivira provides actionable insights into denial patterns specific to your allergy & immunology practice. Our reporting identifies common denial reasons by payer, service line, and provider, allowing your team to address upstream PA submission issues. This feedback loop helps refine prior authorization workflows, reducing future denial rates and improving overall financial performance, aligning with industry benchmarks from sources like the CAQH Index and MGMA Practice Operations and Cost Surveys.

Key Benefits for Allergy & Immunology Practices

  • Automated intake and normalization of denial reasons (CARC/RARC) for biologics and immunotherapies.
  • Intelligent auto-routing of denials to appropriate workflows: appeal, claim correction, or peer-to-peer.
  • FHIR-powered assembly of comprehensive appeal packets with allergy/immunology-specific clinical data from your EMR.
  • Automated appeal submission and diligent tracking with strict timely-filing enforcement.
  • Reduced administrative burden and operational costs associated with manual denial processing.
  • Data-driven insights to identify and mitigate root causes of denials for A&I services.

Frequently asked questions

How does Klivira handle denials for high-cost biologics in allergy & immunology?

Klivira automates the denial workflow for biologics by ingesting denial reasons from various channels, normalizing CARC/RARC codes, and intelligently routing them. For clinical necessity denials, it pulls specific clinical documentation from the EMR via FHIR, such as lab results and prior-line therapy, to build a robust appeal packet for submission and tracking.

Can Klivira integrate with our EMR to pull allergy/immunology-specific clinical data for appeals?

Yes, Klivira leverages SMART on FHIR capabilities to securely integrate with your EMR. This allows the platform to automatically extract relevant clinical documentation, such as detailed notes, lab results, and patient history, essential for substantiating medical necessity during the appeal process for allergy & immunology services.

What common denial reasons in allergy & immunology does Klivira address?

Klivira addresses a wide range of denial reasons prevalent in allergy & immunology, including insufficient documentation for medical necessity (especially for biologics and IVIG), coding errors, lack of prior authorization, and eligibility mismatches. The system normalizes these reasons and routes them to the appropriate automated appeal or correction pathway.

How does Klivira ensure timely filing for allergy & immunology appeal submissions?

Klivira's platform includes robust timely-filing tracking with per-payer window enforcement. It proactively flags upcoming deadlines and automates the submission process through payer portals, APIs, or fax, minimizing the risk of missed appeal windows and ensuring your allergy & immunology practice maximizes revenue recovery.

Does Klivira help identify patterns in A&I denials to prevent future issues?

Absolutely. Klivira provides comprehensive reporting and pattern detection capabilities. It surfaces insights into common denial reasons by payer, specific drug (e.g., Xolair, Dupixent), or procedure, allowing your team to identify root causes and implement upstream improvements in your prior authorization and documentation processes.

Related coverage

Other allergy-immunology prior auth workflows

Ready to automate this workflow for this specialty?

See how Klivira automates prior authorizations for your team.

Request a demo